AbbVie and Johnson & Johnson last week won a patent lawsuit in favor of their oncology drug Imbruvica, which now won’t see generic competition until at least 2032. The legal battle against Alvogen and Natco Pharma began in 2019. Imbruvica, which launched in 2014, is approved to treat several cancers, including chronic lymphocytic leukemia, mantle cell lymphoma and non-Hodgkin lymphoma. Under the pharmacy benefit, Imbruvica holds covered or better status for 71% of all insured lives.
SOURCE: MMIT Analytics, as of 9/1/21